The Psychedelic Pharma Play: Eli Lilly's $10 Billion Gamble?
The recent surge in AtaiBeckley shares, driven by rumors of a potential takeover by pharmaceutical giant Eli Lilly, has left investors and industry observers wondering about the implications for psychedelic medicine.
With reports suggesting that talks are ongoing but no official confirmation from either company, one thing is clear: if a deal materializes, it will be a significant coup for both parties.